YMAB · Categories · Earnings
YMAB - Earnings announcements
Y-mAbs Therapeutics Inc. (YMAB) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for YMAB
- Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsReported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer
- Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and
- Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsReported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv
- Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, May 13, 2025 at 8:00 a.m. ET. A live audio webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.ymabs.com/events-and-presentat
- Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsReported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR
- Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of
- Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsReported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
- Y-mAbs Announces Third Quarter 2024 Conference Call and WebcastNEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):Investors (international):(877) 407-0792(201) 689-8263 To access a live webcast of the update,
- Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsReported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increaseContinued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong KongPart A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran Norman LaFrance, M.D. as Chief Development Officer Cash and cash equivalents of $77.8 million held as of June 30, 2024, reflects $0.8 million cash burn in the six months ended June 30, 2024;
- Y-mAbs Announces Second Quarter 2024 Conference Call and WebcastNEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):(877) 407-0792Investors (international):(201) 689-8263 To access a live webcast of the update, please use this
- Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsReported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumesCash and cash equivalents of $75.7 million as of March 31, 2024, and cash burn of only $2.9 million for the quarter ended March 31, 2024 Management reiterates full year 2024 financial guidance and anticipated cash runway into 2027The Company will host a conference call on Wednesday, May 8, 2024, at 8:00 a.m. ET NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NA
- Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Wednesday, May 8, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Bo Kruse, Chief Financial Officer; and Thomas Gad, Founder, Vice Chair and Chief Business Officer. C
- Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsRecord DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December 31, 2023; Reiterate anticipated cash runway into 2027Management announces full year 2024 financial guidance The Company will host a conference call on Friday, March 1, 2024, at 8:00 a.m. ET NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, t
- Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 1, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Thomas Gad, Founder, Vice Chair and Chief Bu
- Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsQ3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59%U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin LymphomaCash and cash equivalents of $86.6 million as of September 30, 2023, with anticipated cash runway extended into 2027Management updates FY 2023 financial guidance by lowering anticipated operating expenses and use of cash The Company will host a conference call on Tuesday, November 14, 2023, at 9:00 a.m. ET NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,
- Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 14, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Steen Lisby, Chief Scienti
- Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsQ2 2023 DANYELZA® record net product revenues of $20.8 million, driving YoY growth of 112% and a 3% sequential increase compared to Q1 2023Management reiterates FY 2023 financial guidanceDANYELZA marketing authorization granted in Brazil Ongoing patient recruitment in the Phase I GD2-SADA trial Cash and cash equivalents of $87.9 million as of June 30, 2023, anticipated cash runway into 2026The Company will host a conference call on Friday, August 11, 2023, at 9:00 a.m. EDT NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, a
- Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, August 11, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, Founder, Chairman and Interim Chief Executive Officer, Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer, and Vignesh Rajah, Chief Medical Officer. Conference call and webcast details
- Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial GuidanceQ1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 million for FY 2023Ongoing patient recruitment in the Phase I SADA trial Cash and cash equivalents of $92.6 million as of March 31, 2023, anticipated cash runway into the first quarter 2026The Company will host a conference call on Tuesday, May 9, 2023, at 9 a.m. EST NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical com
- Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer. Conference call and webcast details: Investors (domestic): 888-886-7786I
- Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate DevelopmentsQ4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial guidanceFirst ever SADA Phase I trial opened Cash and cash equivalents of $105.8 million as of December 31, 2022, anticipated runway into the first quarter 2026The Company will host a conference call on Friday, March 31, 2023, at 9 a.m. EST NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, ant
- Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 31, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer. Conference call and webcast details: Investors (domestic): 877-407-07
- Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsQ3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022DANYELZA marketing authorization granted in Israel; regulatory filing submitted in BrazilManagement reiterates financial guidance, including anticipated 2022 full-year DANYELZA® revenue of $45-$50 millionCash position of $114.5 million as of September 30, 2022, anticipated runway into mid-2024 The Company will host a conference call on Tuesday, November 8, 2022, at 4 p.m. EST NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and comm
- Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 8, 2022, at 4:00 p.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer and Vignesh Rajah, Chief Medical Officer. Conference call and webcast details: Investors (domest
- Y-mAbs Announces Second Quarter Financial Results and Recent Corporate DevelopmentsOmburtamab BLA Accepted by the FDA with November 2022 PDUFA date Announced IND Clearance for the first GD2-SADA construct YTD DANYELZA® product revenue $20.3 millionManagement reiterates financial guidance, including 2022 full-year DANYELZA® revenue of $45-$50 millionStrong cash position with $133.7 million as of June 30, 2022, anticipated runway into mid-2024 The Company will host a conference call on Tuesday, August 9, 2022, at 9 a.m. EST NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic pro
- Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter that ended June 30, 2022, on Monday, August 8, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, August 9, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; and Sue Smith, Chief Commerical Officer. Conference call and webcast details: Investors (domestic):877-407-0792Investors (international):201-6
- Y-mAbs Announces First Quarter Financial Results and Recent Corporate DevelopmentsCompleted resubmission to the FDA of omburtamab BLADANYELZA® adoption drove a 9% sequential revenue increase to $10.5 millionCompany issues 2022 full-year DANYELZA® revenue guidance of $45-$50 millionStrong cash position with $156.7 million as of March 31, 2022, providing runway through mid-2024 The Company will host a conference call on Tuesday, May 10, 2022, at 9 a.m. ET NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the
- Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter March 31, 2022 on Monday, May 9, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 10, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; and Sue Smith, Chief Commercial Officer. Conference call and webcast details: Investors (domestic):877-407-0792Investors (international):201-689-8263Conference I
- Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate DevelopmentsAnnounced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 DANYELZA® adoption drives sequential revenue increase Completed IND submission to the FDA for first SADA construct Appointed Sue Smith as Chief Commercial Officer Strong cash position with $181.6 million as of December 31, 2021, providing runway through the end of 2023 The Company will host a conference call on Friday, February 25, 2022, at 9 a.m. EST NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of n
- Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, February 25, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer. Conference call and webcast details: Investors (domestic):877-407-0792Investors (international):2
- Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, November 5, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer. Conference call and webcast details: Investors (domestic):877-407-0792Investors (international)
- Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, August 6, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer. Conference call and webcast details: Investors (domestic):855-327-6838 Investors (international):604-2